

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-73 (Cancelled)

74. (New) A medical product comprising a single dry powder dose of tiotropium directly loaded into a container adapted for administration by a dry powder inhaler, wherein the medical product comprises a moisture-tight seal foil fixed to a dry, moisture-tight container;

the dry, moisture-tight container and the moisture-tight seal foil together form a dry, moisture-tight, barrier seal;

the moisture-tight barrier seal prevents ingress of moisture into the single powder dose whereby the original fine particle fraction of the single powder dose is preserved for at least seven days;

the medical product is designed for enabling gradual aerosolization of the powder dose during delivery; and

a delivered fine particle dose of tiotropium from said medical product is generally independent of variations in ambient humidity conditions.

75. (New) The medical product according to claim 74, wherein the original fine particle fraction of the single powder dose is preserved for at least fourteen days.

76. (New) The medical product according to claim 74, wherein the container itself does not emit water.

77. (New) The medical product according to claim 74, wherein the delivered fine particle dose of tiotropium constitutes at least 56 % of a delivered dose.

78. (New) The medical product according to claim 74, wherein the delivered fine particle dose of tiotropium constitutes at least 47 % of a metered dose.

79. (New) The medical product according to claim 74, wherein the tiotropium substance consists of one or more physiologically acceptable salts of tiotropium.

80. (New) The medical product according to claim 74, further comprising lactose as an included excipient.

81. (New) The medical product according to claim 74, wherein the dry, moisture-tight seal foil is constituted of formed or flat aluminum foils, optionally laminated with polymers.

82. (New) The medical product according to claim 74, wherein the dry, moisture-tight container is constituted of a cavity molded from a polymer material.

83. (New) The medical product according to claim 74, wherein the medical product is a separate part adapted for insertion into a dry powder inhaler

84. (New) The medical product according to claim 74, wherein
the medical product is intended for use in the treatment of respiratory disorders.

85. (New) A medical product comprising tiotropium and at least one additional active
pharmaceutical ingredient and optionally including at least one excipient in a single dry
powder medical combination dose directly loaded into a container, wherein

the medical product comprises a moisture-tight seal foil fixed to a dry, moisture-tight
container;

the dry, moisture-tight container and the moisture-tight seal foil together form a dry,
moisture-tight barrier seal;

the moisture-tight barrier seal prevents ingress of moisture whereby the original fine
particle fraction of the single combination dose is preserved for at least seven days;

the combination dose is adapted for administration by a dry powder inhaler;

the medical product is designed for enabling gradual aerosolization of the powder
dose during delivery;

a delivered fine particle dose of the single combination dose is generally independent
of variations in ambient humidity conditions, and

the at least one additional active pharmaceutical ingredient is selected from the
following groups of substances: inhalable steroids, nicotinamide derivatives, beta-agonists,
beta-mimetics, anti-histamines, adenosine A2A receptors, PDE4 inhibitors, dopamine D2
receptor agonists.

86. (New) The medical product according to claim 85, wherein

the original fine particle fraction of the single combination dose is preserved for at
least fourteen days.

87. (New) The medical product according to claim 85, wherein
the container itself does not emit water.

88. (New) The medical product according to claim 85, wherein
the delivered fine particle dose of the single combination dose at least 56 % of a
delivered dose.

89. (New) The medical product according to claim 85, wherein
the delivered fine particle dose of the single combination dose constitutes at least 47
% of a metered dose.

90. (New) The medical product according to claim 85, wherein
the tiotropium substance consists of one or more physiologically acceptable salts of
tiotropium.

91. (New) The medical product according to claims 85, wherein
an included excipient is lactose.

92. (New) The medical product according to claim 85, wherein
the dry, moisture-tight seal foil is constituted of formed or flat aluminum foils,
optionally laminated with polymers.

93. (New) The medical product according to claim 85, wherein
the dry, moisture-tight container is constituted of a cavity molded from a polymer
material.

94. (New) The medical product according to claim 85, wherein
the medical product is a separate part adapted for insertion into the dry powder
inhaler.

95. (New) The medical product according to claim 85, wherein
the medical product is intended for use in the treatment of respiratory disorders.